MedPath

Effects of butyrAte comPared to donor faeces transPlantation on mETabolIsm and saTiEty in patients with metabolic syndrome

Completed
Conditions
insulin resistance, overweight, gutmicrobiota
Registration Number
NL-OMON26960
Lead Sponsor
AMC-uvA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
24
Inclusion Criteria

Caucasian male or postmenopausal female

- 50-70 years old

Exclusion Criteria

-Any Medication use, including PPI and antibiotics in last 3 months

- Drug abuse

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Insulin sensitivity and lipolysis (2-step hyperinsulinemic euglycemic clamp)<br /><br> - Hypothalamic (SPECT-scan), small intestinal (biopsy) and urinal (24h urine sample) serotonin levels in relation to satiety testing
Secondary Outcome Measures
NameTimeMethod
- Faecal energy excretion and short chain fatty acid and bile acid concentration in feces<br /><br>- Dietary intake (dietary lists), resting energy expenditure (calorimetry) and physical activity energy expenditure (accelerometers) <br /><br>- Faecal and small intestinal gut microbiota composition (morning stool samples and biopsies)<br /> <br>- Intestinal permeability (faecal calprotectin levels)<br /> <br>- Intestinal passage time (Sitzmark capsules)<br /><br>- Sympathetic tone (Nexfin)<br /><br>- Inflammatory and lipid-proteomic markers (blood samples) <br /><br>- Liver fat for NAFLD/NASH degree (MRI)
© Copyright 2025. All Rights Reserved by MedPath